Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Lung cancer advocate Don Stranathan takes on the No. 1 cancer killer.
Researchers will test whether this therapy could replace opioids in treating painful swelling of the mouth.
In 2018 alone, 4.9 million middle and high school students used tobacco products.
The patient advocacy coalition I Am Essential sent a letter to the HHS spelling out why the plan is dangerous.
New research suggests some cannabinoid compounds may inhibit or even prevent the growth of colon tumors.
However, successful treatment of HIV, including having a high CD4 count, may buffer against such a risk.
David MacPherson, PhD, discusses the state of SCLC research, how his lab is tackling the disease and what makes him excited for the future.
Keytruda and Bavencio may soon join Opdivo/Yervoy as first-line treatment options for advanced renal cell carcinoma.
The major goal is to understand why the incidence of disease is increasing in young people, for the purposes of prevention and treatment.
Darolutamide delays metastasis and reduces the risk of death in men with high-risk prostate cancer.
NKTR-214 plus Opdivo as first-line therapy had an overall response rate of 48 percent.
The entire brain processes music, giving it the power to influence mood and memory and making it a powerful therapeutic tool.
These men lived for a median of 30 months compared to 26 months for white men.
Once unheard-of survival rates seen among patients with advanced Merkel cell carcinoma.
Cancer rarely appears in the fossil record—when it does, researchers jump at the chance to study it.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.